PMID- 21454005 OWN - NLM STAT- MEDLINE DCOM- 20110823 LR - 20151119 IS - 1579-2129 (Electronic) IS - 0300-2896 (Linking) VI - 47 IP - 4 DP - 2011 Apr TI - Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. PG - 176-83 LID - 10.1016/j.arbres.2010.12.003 [doi] AB - INTRODUCTION: Exacerbations of chronic obstructive pulmonary disease (COPD) are characterised by an inflammatory and systemic response that persists for some time after their clinical resolution. The mechanisms of this inflammatory process are not well known. OBJECTIVES: To explore the inflammatory changes and possible mechanisms during COPD exacerbation. METHODS: We determined the inflammatory cell concentrations in blood and sputum, nitric oxide in exhaled air (FeNO), C-reactive protein (CRP) in plasma, cytokines (IL-6, 8, 1beta, 10, 12, TNF-alpha) and SLPI (leukocyte protease inhibitor) and total antioxidant status (TAS) in blood and sputum, the activity of nuclear kappa B factor (NF-kappa B) and of the histone deacetylase enzyme (HDAC) in 17 patients during COPD exacerbation and in stable phase, as well as in 17 smoker and 11 non-smoker controls. RESULTS: COPD exacerbations are characterised by high levels of FeNO (p<0.05), plasma CRP (p<0.001) and IL-8, IL-1B, IL-10 in sputum (p<0.05) greater activation of NF-kappa appaB in sputum macrophages compared with stable COPD and controls. During the stable phase, there continue to be high levels of oxidative stress, SLPI, IL-8, IL-6 and TNF-alfa, with no observed changes in either HDAC activity or in the amount of neutrophils in sputum, despite presenting a significant improvement (p<0.05) in lung function. CONCLUSIONS: Changes were observed in different pulmonary and systemic inflammatory markers during COPD exacerbation, which did not completely resolve during stable phase. However, current treatment does not allow for HDAC activity to be modified, which limits its anti-inflammatory effects. CI - Copyright (c) 2010 SEPAR. Published by Elsevier Espana. All rights reserved. FAU - Kersul, Ana L AU - Kersul AL AD - Servicio de Neumologia, Hospital Universitario Son Dureta, Palma de Mallorca, Spain. FAU - Iglesias, Amanda AU - Iglesias A FAU - Rios, Angel AU - Rios A FAU - Noguera, Aina AU - Noguera A FAU - Forteza, Aina AU - Forteza A FAU - Serra, Enrique AU - Serra E FAU - Agusti, Alvar AU - Agusti A FAU - Cosio, Borja G AU - Cosio BG LA - eng PT - Journal Article DEP - 20110331 PL - Spain TA - Arch Bronconeumol JT - Archivos de bronconeumologia JID - 0354720 RN - 0 (Antioxidants) RN - 0 (Biomarkers) RN - 0 (Cytokines) RN - 0 (NF-kappa B) RN - 0 (SLPI protein, human) RN - 0 (Secretory Leukocyte Peptidase Inhibitor) RN - 31C4KY9ESH (Nitric Oxide) RN - 9007-41-4 (C-Reactive Protein) RN - EC 3.5.1.98 (Histone Deacetylases) SB - IM MH - Aged MH - Antioxidants/analysis MH - Biomarkers MH - Blood Cells/pathology MH - Breath Tests MH - C-Reactive Protein/analysis MH - Cytokines/blood MH - Female MH - Gene Expression Regulation MH - Histone Deacetylases/blood MH - Humans MH - Inflammation/*metabolism MH - Macrophages/metabolism/pathology MH - Male MH - Middle Aged MH - NF-kappa B/*metabolism MH - Nitric Oxide/analysis MH - Oxidative Stress MH - Pulmonary Disease, Chronic Obstructive/*metabolism/physiopathology MH - Secretory Leukocyte Peptidase Inhibitor/blood MH - Smoking/metabolism MH - Spirometry MH - Sputum/chemistry/cytology MH - Transcription, Genetic EDAT- 2011/04/02 06:00 MHDA- 2011/08/24 06:00 CRDT- 2011/04/02 06:00 PHST- 2010/07/22 00:00 [received] PHST- 2010/12/04 00:00 [revised] PHST- 2010/12/13 00:00 [accepted] PHST- 2011/04/02 06:00 [entrez] PHST- 2011/04/02 06:00 [pubmed] PHST- 2011/08/24 06:00 [medline] AID - S0300-2896(11)00027-5 [pii] AID - 10.1016/j.arbres.2010.12.003 [doi] PST - ppublish SO - Arch Bronconeumol. 2011 Apr;47(4):176-83. doi: 10.1016/j.arbres.2010.12.003. Epub 2011 Mar 31.